Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited

4.98
USD
-0.07
(-1.39%)
0.46EPS
Feb 23Next Earn

Important Dates

Clinuvel Pharmaceuticals Limited's next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of June 30, 2026, Clinuvel Pharmaceuticals Limited has 50.49M shares outstanding.

Shares Outstanding50.49M

Financial Position

As of June 30, 2026, Clinuvel Pharmaceuticals Limited maintains a current ratio of 14.81, meaning it holds 14.8x the short-term assets needed to cover near-term liabilities.

Current Ratio14.81
Quick Ratio14.34
Debt / Equity0.71
Debt / EBITDA0.05

Financial Efficiency

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited posted a return on equity (ROE) of 13.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.14, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.01 indicates how many times Clinuvel Pharmaceuticals Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)13.21
Return on Assets (ROA)11.97
Return on Invested Capital (ROIC)10.47
Return on Capital Employed (ROCE)13.14
Inventory Turnover2.01

Taxes

USD

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited recorded 9.51M in income tax expense. That works out to an effective tax rate of 28.84, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.98M, leaving 23.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax9.51M
Effective Tax Rate28.84

Stock Price Statistics

USD

These figures are as of the close on November 16, 2026.

50-Day Moving Average5.48

Income Statement

USD

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited generated 65.07M in revenue and converted that into 23.47M in net income, yielding earnings per share of 0.46. EBITDA reached 28.05M, while operating income came in at 27.37M.

Revenue65.07M
Gross Profit54.13M
Operating Income27.37M
Pretax Income32.98M
Net Income23.47M
EBITDA28.05M
EBIT27.37M
Earnings Per Share (EPS)0.46

Balance Sheet

USD

As of June 30, 2026, Clinuvel Pharmaceuticals Limited holds 174.43M in cash and equivalents against 1.34M in total debt, resulting in a net debt position of -174.43M. Total book value stands at 188.85M, with working capital of 183.68M providing operational flexibility.

Cash & Cash Equivalents174.43M
Total Debt1.34M
Net Debt-174.43M
Equity (Book Value)188.85M
Book Value Per Share3.74
Working Capital183.68M

Cash Flow

USD

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-1.11M

Margins

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited posted a gross margin of 83.18, reflecting its pricing power and cost economics. The operating margin of 42.06 and net profit margin of 36.07 provide insight into operational efficiency.

Gross Margin83.18
Operating Margin42.06
Pretax Margin50.69
Profit Margin36.07
EBITDA Margin43.11

Dividends & Yields

USD

Over the twelve months ended June 30, 2026, Clinuvel Pharmaceuticals Limited paid dividends of 0.03 per share. The dividend payout ratio of 7.39 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Dividend Per Share0.03
Payout Ratio7.39